<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>319</serviceExecutionTime><Drug id="6074"><DrugName>levamisole</DrugName><DrugNamesKey><Name id="43058603">Ascaridil</Name><Name id="42769204">Ergamisol</Name><Name id="42757819">levamisole</Name></DrugNamesKey><DrugSynonyms><Name><Value>Ketrax</Value></Name><Name><Value>levamisole</Value><Types><Type>BAN</Type><Type>INN</Type></Types></Name><Name><Value>Decaris</Value></Name><Name><Value>KW-2299</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Ergamisol</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>NSC-177023</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Ascaridil</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>14769-73-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17421">Janssen Pharmaceutica NV</CompanyOriginator><CompaniesPrimary><Company id="17392">Janssen-Cilag Ltd</Company><Company id="17421">Janssen Pharmaceutica NV</Company></CompaniesPrimary><CompaniesSecondary><Company id="17416">Janssen LP</Company></CompaniesSecondary><CrossReferences><SourceEntity id="6074" type="Drug"><TargetEntity id="273560" type="siDrug">Levamisole hydrochloride</TargetEntity></SourceEntity><SourceEntity id="17392" type="Company"><TargetEntity id="4296968679" type="organizationId">Janssen-Cilag Ltd</TargetEntity></SourceEntity><SourceEntity id="17416" type="Company"><TargetEntity id="5000410549" type="organizationId">Janssen LP</TargetEntity></SourceEntity><SourceEntity id="17421" type="Company"><TargetEntity id="4295987443" type="organizationId">Janssen Pharmaceutica NV</TargetEntity></SourceEntity><SourceEntity id="1055" type="ciIndication"><TargetEntity id="C20" type="ICD10"/><TargetEntity id="154.1" type="ICD9"/><TargetEntity id="10038038" type="MEDDRA"/><TargetEntity id="D012004" type="MeSH"/><TargetEntity id="-796050081" type="omicsDisease"/><TargetEntity id="640" type="siCondition"/></SourceEntity><SourceEntity id="150" type="ciIndication"><TargetEntity id="10061201" type="MEDDRA"/><TargetEntity id="D006373" type="MeSH"/><TargetEntity id="-1420180726" type="omicsDisease"/><TargetEntity id="837" type="siCondition"/></SourceEntity><SourceEntity id="152" type="ciIndication"><TargetEntity id="10019731" type="MEDDRA"/><TargetEntity id="D019694" type="MeSH"/><TargetEntity id="-1284790527" type="omicsDisease"/><TargetEntity id="429" type="siCondition"/></SourceEntity><SourceEntity id="230" type="ciIndication"><TargetEntity id="10028980" type="MEDDRA"/><TargetEntity id="D009369" type="MeSH"/><TargetEntity id="1855" type="siCondition"/></SourceEntity><SourceEntity id="767" type="ciIndication"><TargetEntity id="C18" type="ICD10"/><TargetEntity id="10009944" type="MEDDRA"/><TargetEntity id="D003110" type="MeSH"/><TargetEntity id="-729056112" type="omicsDisease"/><TargetEntity id="593" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="2638" type="Action"><TargetEntity id="4622" type="Mechanism">Drugs Targeting Plasmodium falciparum Proteins</TargetEntity><TargetEntity id="4959" type="Mechanism">Drugs Targeting Parasite Proteins</TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Neoplasm - US - Jan-1990</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1055">Rectal tumor</Indication><Indication id="230">Neoplasm</Indication><Indication id="767">Colon tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="150">Helminth infection</Indication><Indication id="152">Hepatitis B virus infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="991">Antiviral</Action><Action id="59620">Unspecified drug target</Action><Action id="1545">Anticancer</Action><Action id="2638">Antiparasitic</Action></ActionsSecondary><Technologies><Technology id="603">Systemic formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra><Ephmra><Code>P</Code><Name>PARASITOLOGY</Name></Ephmra></EphmraCodes><LastModificationDate>2019-03-23T08:42:27.000Z</LastModificationDate><ChangeDateLast>2017-08-07T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Levamisole (Ascaridil) was initially developed and launched by &lt;ulink linkID="17332" linkType="Company"&gt;Janssen&lt;/ulink&gt; as an antihelmintic and for the treatment of cancer and prolonged viral hepatitis. It has also been launched in combination with fluorouracil for the treatment of Dukes C colon cancer in the US and is awaiting registration in Europe [&lt;ulink linkID="135015" linkType="Reference"&gt;135015&lt;/ulink&gt;]. In October 1977, Janssen-Cilag received marketing approval for the drug in France; however in August 2010, the authorization status of the drug was revoked [&lt;ulink linkID="1351537" linkType="Reference"&gt;1351537&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2004, the drug was discontinued in Germany [&lt;ulink linkID="2131924" linkType="Reference"&gt;2131924&lt;/ulink&gt;]. By January 2006, the drug was discontinued in Australia [&lt;ulink linkID="2131927" linkType="Reference"&gt;2131927&lt;/ulink&gt;]. By January 2007, the drug was discontinued in Belgium [&lt;ulink linkID="2131929" linkType="Reference"&gt;2131929&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In October 1977, Janssen-Cilag received marketing approval for the drug in France; however in August 2010, the authorization status of the drug was revoked [&lt;ulink linkID="1351537" linkType="Reference"&gt;1351537&lt;/ulink&gt;]. By January 2004, the drug was discontinued in Germany [&lt;ulink linkID="2131924" linkType="Reference"&gt;2131924&lt;/ulink&gt;]. By January 2007, the drug was discontinued in Belgium [&lt;ulink linkID="2131929" linkType="Reference"&gt;2131929&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By November 2012, the drug had been approved in Brazil as Ascaridil [&lt;ulink linkID="1647989" linkType="Reference"&gt;1647989&lt;/ulink&gt;]. In November 2017, the drug was launched in Brazil [&lt;ulink linkID="2131922" linkType="Reference"&gt;2131922&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;By January 2006, the drug was discontinued in Australia [&lt;ulink linkID="2131927" linkType="Reference"&gt;2131927&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In May 2000, results of multiple clinical trials examining levamisole in adjuvant settings, with 5-fluorouracil, L-folinic acid or interferon alpha 2C in colon cancer patients were presented at the 36th ASCO meeting in New Orleans, LA. General conclusions were that there is no significant benefit of using levamisole in combination with the other anticancer agents and thus levamisole is not a promising adjuvant component [&lt;ulink linkID="370114" linkType="reference"&gt;370114&lt;/ulink&gt;], [&lt;ulink linkID="370091" linkType="reference"&gt;370091&lt;/ulink&gt;], [&lt;ulink linkID="370073" linkType="reference"&gt;370073&lt;/ulink&gt;], [&lt;ulink linkID="370072" linkType="reference"&gt;370072&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2000, results from the 'QUASAR' trials (145 centers, in nine countries) were presented at 4th International Conference for Colorectal Cancer in Paris, France. One group of patients was randomized to receive levamisole or placebo. Another group received low- or high-dose folinic acid. All patients had undergone the complete resection of colorectal cancer and were pretreated with 5-fluorouracil. The results indicated that there was no improvement in survival and recurrence with levamisole treatment, and an increase in dermatological toxicity was observed [&lt;ulink linkID="371998" linkType="reference"&gt;371998&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A 5.5 year follow up of patients treated with the drug alone or with 5-FU and with surgery revealed that the combination reduced cancer recurrence and cancer deaths compared with surgery alone but that by itself it was not superior to surgery [&lt;ulink linkID="189965" linkType="reference"&gt;189965&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A US trial in renal tumor patients was halted in 1996 due to the lack of clinical response and toxicity associated with a 5 mg/kg dose of every second day [&lt;ulink linkID="222791" linkType="reference"&gt;222791&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The compound  is further being developed (in clinical trials) for other indications, such as chronic hepatitis B (in combination with interferon) [&lt;ulink linkID="154745" linkType="reference"&gt;154745&lt;/ulink&gt;] and HIV [&lt;ulink linkID="154755" linkType="reference"&gt;154755&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17392">Janssen-Cilag Ltd</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="230">Neoplasm</Indication><StatusDate>2017-11-08T00:00:00.000Z</StatusDate><Source id="2131922" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17421">Janssen Pharmaceutica NV</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="230">Neoplasm</Indication><StatusDate>1990-01-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17421">Janssen Pharmaceutica NV</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="767">Colon tumor</Indication></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17421">Janssen Pharmaceutica NV</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="1055">Rectal tumor</Indication><Source id="222791" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17416">Janssen LP</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="230">Neoplasm</Indication><StatusDate>2004-01-01T00:00:00.000Z</StatusDate><Source id="2131924" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17392">Janssen-Cilag Ltd</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="767">Colon tumor</Indication><StatusDate>2010-08-24T00:00:00.000Z</StatusDate><Source id="1351537" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17416">Janssen LP</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="767">Colon tumor</Indication><StatusDate>2006-01-01T00:00:00.000Z</StatusDate><Source id="2131927" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17421">Janssen Pharmaceutica NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="152">Hepatitis B virus infection</Indication><StatusDate>2007-01-01T00:00:00.000Z</StatusDate><Source id="2131929" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17421">Janssen Pharmaceutica NV</Company><Country id="EU">EU</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="767">Colon tumor</Indication><StatusDate>2007-01-01T00:00:00.000Z</StatusDate><Source id="2131929" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17421">Janssen Pharmaceutica NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="230">Neoplasm</Indication><StatusDate>2007-01-01T00:00:00.000Z</StatusDate><Source id="2131929" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17421">Janssen Pharmaceutica NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="150">Helminth infection</Indication><StatusDate>2007-01-01T00:00:00.000Z</StatusDate><Source id="2131929" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17392">Janssen-Cilag Ltd</Company><Country id="FR">France</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="767">Colon tumor</Indication><StatusDate>1977-10-24T00:00:00.000Z</StatusDate><Source id="1351537" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17416">Janssen LP</Company><Country id="DE">Germany</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="230">Neoplasm</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17416">Janssen LP</Company><Country id="AU">Australia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="767">Colon tumor</Indication><StatusDate>1996-09-13T00:00:00.000Z</StatusDate><Source id="219453" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17421">Janssen Pharmaceutica NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="150">Helminth infection</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17421">Janssen Pharmaceutica NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="230">Neoplasm</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17421">Janssen Pharmaceutica NV</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="152">Hepatitis B virus infection</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17421">Janssen Pharmaceutica NV</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="767">Colon tumor</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17392">Janssen-Cilag Ltd</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="230">Neoplasm</Indication><StatusDate>2012-11-12T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>4 references added [&lt;ulink url="utility.reference?i_reference_id=2131929" linkType="reference" linkID="2131929"&gt;2131929&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2131924" linkType="reference" linkID="2131924"&gt;2131924&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2131922" linkType="reference" linkID="2131922"&gt;2131922&lt;/ulink&gt;, &lt;ulink url="utility.reference?i_reference_id=2131927" linkType="reference" linkID="2131927"&gt;2131927&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>c1ccc(cc1)[C@H]2CN3CCSC3=N2</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="1019860" number="CN-01389214" title="Compound liniment for treating autoimmune disease"/><PatentFamily id="102161" number="US-04150141" title="Treatment for scabies"/><PatentFamily id="1037018" number="WO-2011150745" title="&lt;i&gt;Mycobacterium tuberculosis&lt;/i&gt; Ag85ab chimeric gene vaccine, its preparation method and application"/><PatentFamily id="1124163" number="CN-01027859" title="Process for preparing antihelminth cream"/><PatentFamily id="1196840" number="AU-00605704" title="Anthelmintic Formulations"/><PatentFamily id="1208269" number="WO-00024368" title="Reduction Of Hair Growth"/><PatentFamily id="1261773" number="WO-03041654" title="Anti-estrogen and immune modulator combinations for treating breast cancer"/><PatentFamily id="1311569" number="WO-00075311" title="Recombinant Nematode Nicotinic Receptor And Uses"/><PatentFamily id="1344396" number="US-04584305" title="Aiding The Regression Of Neoplastic Disease With 2,3,5,6-Tetrahydro-6-Phenylimidazo(2,1-b)Thiazole"/><PatentFamily id="1352509" number="WO-09315716" title="Levamisole Or Tetramisole Based Pour-On Formulations"/><PatentFamily id="1354455" number="BR-09802431" title="Composicao Parasiticida Compreendendo Ivermectina Em Associacao Com Pelo Menos Um Outro Ingrediente Ativo, Processo Para Sua Preparacao, Processo Para Combate A Parasitas Em Um Aninal De Sangue Quente E Uso Da Referida Composicao."/><PatentFamily id="1582989" number="US-04153678" title="Levamisole Effervescent Tablets"/><PatentFamily id="1651247" number="CN-01076611" title="Exterior applied medicine 'yiganzhuanyin liquid' for transforming surface antigen of hepatitis B from positive to negative"/><PatentFamily id="1703622" number="WO-2011157936" title="Compositions containing flavones and anthelmintics"/><PatentFamily id="1793200" number="EP-00142191" title="Process for isolating levamisole from tetramisole"/><PatentFamily id="1793781" number="HU-00203108" title="Process For Producing Levamisol"/><PatentFamily id="1836328" number="CN-01290526" title="Medicine for expelling live roundworn in biliary tract"/><PatentFamily id="1878440" number="US-04166824" title="Chiral Rhodium-Diphosphine Catalyst Capable Of Catalytic Reduction Of A Tetramisole Precursor To Give A Significant Excess Of The Desired S-(-)Isomer, Levamisole"/><PatentFamily id="1904858" number="WO-09215297" title="Agents, especially levamisole, against the human immunodeficiency virus."/><PatentFamily id="191055" number="CN-01233311" title="Compound ointment for treating fungal skin disease"/><PatentFamily id="2044199" number="CN-100364530" title="Novel levamisole formulation for chronic rhinitis"/><PatentFamily id="212715" number="WO-2005079842" title="Immunological adjuvant"/><PatentFamily id="2322769" number="US-04090025" title="Intermediates for synthesis of tetramisole, levamisole and their derivatives"/><PatentFamily id="234071" number="SU-01166800" title="Method Of Determining The Individual Sensitivity Installation For Patients Ill With Rhematoi Arthritis To Levamisole"/><PatentFamily id="2493420" number="KR-01261791" title="The activation of the living cell alkali-proof phytase is the fluorescence probe for the detection."/><PatentFamily id="2781363" number="EP-02762154" title="Vaccine composition for transdermal administration"/><PatentFamily id="2781364" number="EP-02762153" title="Vaccine composition for mucosal administration"/><PatentFamily id="2790667" number="WO-2014132227" title="Transdermal formulations"/><PatentFamily id="2814595" number="CN-103937742" title="A culture method of an immune cell for simultaneously activating cd4+ and cd8 + t-cells"/><PatentFamily id="2879865" number="CN-104230959" title="Preparation method of levamisole hydrochloride"/><PatentFamily id="2956561" number="CN-104623124" title="Chinese medicine and western medicine for treatment of sore gums"/><PatentFamily id="3054044" number="PL-00220160" title="Method for determining levamisole in plant tissue"/><PatentFamily id="3071668" number="US-09880154" title="Method for screening drugs and animal model for same"/><PatentFamily id="3176655" number="CN-105497875" title="Compound nursing agent for anus week eczema and preparation method thereof"/><PatentFamily id="3280060" number="CN-105748516" title="Medicine composition of treating repeated oral cavity anabrosis"/><PatentFamily id="3304513" number="WO-2011143479" title="Injectable parasiticidal formulations of levamisole and macrocyclic lactones"/><PatentFamily id="3374678" number="CN-105920105" title="Oral administration preparation for auxiliary treatment of cancer chemotherapy"/><PatentFamily id="3374701" number="CN-105920081" title="Compound preparation for treating appendix granuloma and preparation method thereof"/><PatentFamily id="3485019" number="CN-106177939" title="Vaccine adjuvant and application"/><PatentFamily id="3503960" number="CN-106236813" title="A maca ginseng tablet and preparation method thereof"/><PatentFamily id="3557317" number="CN-106389429" title="A western medicine composition for treating senile dementia and its application"/><PatentFamily id="3568142" number="CN-106420733" title="A levamisole mebendazol tablet and preparation method thereof"/><PatentFamily id="3579931" number="CN-106474159" title="Medicine for treating oral ulcer and preparation method thereof"/><PatentFamily id="3584677" number="CN-106491725" title="A medicine composition for treating oral cavity anabrosis and preparation method thereof"/><PatentFamily id="3584788" number="CN-106491602" title="A medicine for treating radiation enteritis"/><PatentFamily id="3587043" number="WO-2017052403" title="Preparing a tablet with a mechanism for enhancing the therapeutic effectiveness of a drug using a nano-dose of microrna"/><PatentFamily id="3591146" number="CN-106511342" title="A medicine for treating radiation enteritis and its preparation method and application"/><PatentFamily id="3640348" number="CN-106619735" title="A medicine for curing acute herpes stomatitis and preparation method thereof"/><PatentFamily id="3649079" number="CN-106668248" title="A pharmaceutical composition for treating vitligo"/><PatentFamily id="3678575" number="CN-106727537" title="Pharmaceutical composition for senile dementia and its application"/><PatentFamily id="3698550" number="CN-106822004" title="Levamisole hydrochloride pharmaceutical composition"/><PatentFamily id="4183678" number="WO-2018160762" title="Functional ligands to drug compounds"/><PatentFamily id="4465337" number="CN-109568302" title="Medicine for curing late liver cancer compound and application thereof"/><PatentFamily id="4508757" number="CN-109718235" title="A medicine for treating bile duct cancer compound and application thereof"/><PatentFamily id="451078" number="CN-102675346" title="Levamisole hydrochloride organic acid salt, synthesis method thereof and a pharmaceutical composition"/><PatentFamily id="521766" number="CN-102161670" title="Method and device for desorbing active carbon in levamisole hydrochloride by continuous vacuum switching way integrating yarn filtration and membrane filtration"/><PatentFamily id="607258" number="KR-08900906" title="Process For Preparing Injectable Nitroxynil And Levamisole Preparation Against Liver Flukes And Gastrointestinal Roundworms"/><PatentFamily id="678288" number="EP-00049731" title="Anthelmintic Levamisole Gel Compositions"/><PatentFamily id="68300" number="CN-101586141" title="High-flux fast sieving method for Apostichopus japonicas immunopotentiating agent"/><PatentFamily id="728804" number="CN-01391954" title="Composition for reinforcing nucleic acid vaccine immunity and its producing method and using method"/><PatentFamily id="730247" number="CN-01785183" title="For injection with function of improving human immunity"/><PatentFamily id="866662" number="WO-03037331" title="Use of tetramisole and its derivatives against spore producing microorganisms"/><PatentFamily id="871235" number="CN-102060863" title="Method for extracting levamisole hydrochloride by integration of continuous rectification and roller crystallization"/><PatentFamily id="901894" number="CS-00274305" title="Vaccine Against Levamisole-Potentiated Tapeworm Taenia Crassiceps Infection And Method Of Its Preparation"/><PatentFamily id="915706" number="CA-01112170" title="Tetramisole And Levamisole Pour-On Compositions And Methods Of Use"/><PatentFamily id="916297" number="US-04087611" title="Optically active 1-oxyethyl-4-phenyl-2-imidazolidones"/><PatentFamily id="923079" number="WO-2008028324" title="Novel levamisole formulation for allergic rhinitis"/><PatentFamily id="971007" number="NZ-00570591" title="Anthelmintic compositions"/><PatentFamily id="975225" number="JP-62205089" title="6-Phenyl-2,3,5,6-Tetrahydroimidazo(2,1-B)Thiazole Cinnamate And Purification Of Levamisole Therewith"/><PatentFamily id="991037" number="WO-00243618" title="Methods For Contemporaneous Administration Of Levamisole And 5-Fluorouracil"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>26</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>41</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>5</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pathogenes Inc" id="1005845"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Targent Inc" id="1006011"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chongqing University" id="1006658"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ocean University of China" id="1014788"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="China Agricultural University" id="1015963"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Simcere Pharmaceutical Group" id="1023261"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nanjing Baijingyu Pharmaceutical Factory" id="1027898"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Industry-Academic Cooperation Foundation Dankook University" id="1031908"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhengzhou University" id="1033848"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="309th Hospital of Chinese People's Liberation Army" id="1060210"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="College of Life Sciences" id="1062571"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shanghai H&amp;G Biotechnology Co" id="1066720"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Luoyang Pulike Bio-engineering Co Ltd" id="1075849"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Changzhou Yabang Qihui Pharmaceutical Chemical Engineering Co Ltd" id="1076210"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Asia (Beijing) International Liver Research Institute" id="1078426"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Yanjiang Chemical Resources Development Research Institute Co Ltd" id="1078934"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Base Pair Biotechnologies Inc" id="1102060"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lianyungang Yahui Pharmachem Co Ltd" id="1102485"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hubei Huasai Biopharmaceutical Technology Co Ltd" id="1102830"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="KAMP Medicine Co Ltd" id="1123899"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ji'An Yumeili Health Industry Co. Ltd" id="1142038"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhengzhou Lydia Medical Technology Co. Ltd." id="1145895"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhengzhou Zhangmeng Network Technology Co Ltd" id="1147029"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Henan Baling Electronic Technology Co Ltd" id="1147563"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayer AG" id="14455"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boehringer Ingelheim International GmbH" id="14881"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Institut National de la Recherche Agronomique" id="17236"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kaneka Corp" id="17639"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nitto Denko Corp" id="18574"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Procter &amp; Gamble Co" id="19143"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Gedeon Richter Ltd" id="19441"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Auckland" id="20647"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>16</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>16</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Texas System" id="21864"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Spectrum Pharmaceuticals Inc" id="24232"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Babraham Institute" id="24725"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biophage Pharma Inc" id="28464"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>